Trials / Completed
CompletedNCT03298464
Study of NGM313 in Obese Participants
A Phase 1B, Single Center, Randomized, Open Label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single NGM313 Dose or Daily Oral Pioglitazone in Obese Participants With Insulin Resistance and Increased Liver Fat
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGM313 | Subcutaneous injection |
| DRUG | Pioglitazone | White to off-white round tablet |
Timeline
- Start date
- 2017-09-11
- Primary completion
- 2018-06-19
- Completion
- 2018-07-17
- First posted
- 2017-10-02
- Last updated
- 2019-03-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03298464. Inclusion in this directory is not an endorsement.